Completed PHASE3 INTERVENTIONAL 2-arm NCT01872611

Nepafenac Once Daily for Macular Edema - Study 2

Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery

Sponsor: Alcon Research

Conditions Cataract Non-Proliferative Diabetic Retinopathy

Interventions Nepafenac Ophthalmic Suspension, 0.3% Prednisolone acetate Vehicle

Updated 6 times since 2017 Last updated: Jun 22, 2016 Started: Jun 30, 2013 Primary completion: May 31, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01872611, this PHASE3 trial focuses on Cataract and Non-Proliferative Diabetic Retinopathy and remains completed. Sponsored by Alcon Research, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alcon Research

Data source: Alcon Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.